Cushing's disease preceded by generalized glucocorticoid resistance: clinical consequences of a novel, dominant-negative glucocorticoid receptor mutation.
Generalized glucocorticoid resistance is associated with chronic hyperactivation of the hypothalamic-pituitary-adrenal axis, compensating for impaired glucocorticoid receptor function. We report a unique patient with sporadic generalized glucocorticoid resistance who, at age 33, presented with infertility and hypertension and, at 38, developed pituitary Cushing's disease. Leukocyte-binding studies revealed normal affinity of the glucocorticoid receptor but a reduction of binding sites by 50%. [3H]thymidine incorporation by this patient's lymphocytes was not suppressible by dexamethasone. He had a novel heterozygous missense mutation in the glucocorticoid receptor gene (isoleucine 559 to asparagine 559). The mutant receptor exhibited a strong dominant-negative effect on the ability of the wild-type receptor to induce gene transcription in vitro. The mutation was present in all of the patient's cultured lymphoblasts and fibroblasts as well as in 50% of his sperm, as demonstrated by single-cell polymerase chain reaction; it was not present in his parents and seven siblings. This novel mutation was thus both de novo and present in the germ line. Immunohistochemical staining of this patient's pituitary corticotropinoma revealed accumulation of p53 protein, indicating the presence of a putative somatic oncogenic mutation in the p53 gene in the tumor cells. Investigation of the lymphoblast and skin fibroblast cultures for p53 abnormalities did not show any aberration. Thus, a novel de novo germ line mutation of the glucocorticoid receptor with strong dominant-negative activity caused severe sporadic generalized glucocorticoid resistance, which preceded corticotroph adenoma formation. The latter probably was due to the combined effects of chronic corticotroph hyperstimulation, decreased glucocorticoid negative feedback, and at least one subsequent somatic defect in the control of the cell cycle.
Karl
M
M
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-1862, USA.
Lamberts
S W
SW
Koper
J W
JW
Katz
D A
DA
Huizenga
N E
NE
Kino
T
T
Haddad
B R
BR
Hughes
M R
MR
Chrousos
G P
GP
D000328:Adult; D000818:Animals; D019556:COS Cells; D002460:Cell Line; D002461:Cell Line, Transformed; D003480:Cushing Syndrome / Q000235:genetics* / Q000378:metabolism; D018076:DNA, Complementary; D003907:Dexamethasone / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000378:metabolism*; D006801:Humans; D008297:Male; D009154:Mutation; D010375:Pedigree; D011965:Receptors, Glucocorticoid / Q000235:genetics* / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism; D014316:Tritium; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism
D018076:DNA, Complementary; D005938:Glucocorticoids; D011965:Receptors, Glucocorticoid; D016159:Tumor Suppressor Protein p53; D014316:Tritium; D003907:Dexamethasone; D013936:Thymidine